Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CorMedix (CRMD) EPS (Basic) (2016 - 2025)

CorMedix's EPS (Basic) history spans 14 years, with the latest figure at $0.13 for Q4 2025.

  • For Q4 2025, EPS (Basic) fell 45.83% year-over-year to $0.13; the TTM value through Dec 2025 reached $2.25, up 825.81%, while the annual FY2025 figure was $2.25, 850.0% up from the prior year.
  • EPS (Basic) for Q4 2025 was $0.13 at CorMedix, down from $1.52 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $1.52 in Q3 2025 and bottomed at -$0.25 in Q2 2023.
  • The 5-year median for EPS (Basic) is -$0.19 (2022), against an average of -$0.01.
  • The largest annual shift saw EPS (Basic) tumbled 58.33% in 2022 before it soared 3140.0% in 2025.
  • A 5-year view of EPS (Basic) shows it stood at -$0.21 in 2021, then increased by 4.76% to -$0.2 in 2022, then grew by 0.42% to -$0.2 in 2023, then surged by 220.51% to $0.24 in 2024, then plummeted by 45.83% to $0.13 in 2025.
  • Per Business Quant, the three most recent readings for CRMD's EPS (Basic) are $0.13 (Q4 2025), $1.52 (Q3 2025), and $0.28 (Q2 2025).